The Business Models Holding Up In The Rout
Beyond the dismal parade of ASX-listed victims ensuing from the corona crisis, a low-profile cluster of stocks is benefiting from the mayhem.
Read MoreTag: CUV
Clinuvel Pharmaceuticals – Minimal Concerns Over FDA Delay
Investors were quick to drop Clinuvel shares after an update on the Prescription Drug User Fee Act (PDUFA) goal date for its SCENESSE product. However, analysts at Moelis note that while any delay around FDA approval is disappointing, it’s likely only a timing issue.
Read More